Industry meetings continue to reinforce the changing landscape of the drug pipeline and the influence of biologic drug products in driving this change.  At the recent DCAT Week, hosted by the Drug, Chemical and Associated Technologies Association, Josef Bossart, of PharmaCircle, provided an excellent overview of historic trends and current forecasts.